The UK and US have reached a significant commercial pact that will ensure zero tariffs on UK medicine exports entering the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on medicines through the NHS. This pledge secures that tariffs on these key exports will be held at zero for a duration of three years.
This agreement is in response to recent threats to significantly raise tariffs on patented pharmaceutical imports, with figures floated up to one hundred percent.
"This arrangement with the United Kingdom strengthens the global environment for cutting-edge drugs and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Impact
Pharmaceuticals represent one of the UK's largest export categories to the US, which is by far the biggest market for leading UK drugmakers.
Export figures indicate that in the one-year period leading up to the third quarter, the UK shipped pharmaceutical products worth billions to the US. This figure made up nearly one-fifth of British export trade in that period.
"This guarantee protects jobs, increases funding and sets the stage for the UK to emerge as a global hub for life sciences," a minister stated.
Detailed UK Commitments
The agreement includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to raise overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The percentage drug companies must refund to the NHS to control costs will be restricted at 15%. Last year, rebates were more than twenty percent.
Broader Context
The pact comes amid a ongoing row between the drug companies and the ministers over drug pricing and regulatory access.
This friction were exacerbated by claims that US customers were charged significantly more for the same drugs than patients in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been halted or cancelled, while substantial investments have been announced toward US facilities.
One official publicly accepted that the NHS must invest a greater share on medicines, noting that its spending on drugs had shrunk as a share of its overall budget over the previous ten-year period.
